PMID- 31651902
OWN - NLM
STAT- MEDLINE
DCOM- 20191106
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 43
DP  - 2019 Oct
TI  - Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced 
      nonsmall cell lung cancer: A meta-analysis.
PG  - e17705
LID - 10.1097/MD.0000000000017705 [doi]
LID - e17705
AB  - BACKGROUND: The aim of this meta-analysis is to investigate the impact of 
      Osimertinib on treatment efficacy in advanced nonsmall cell lung cancer (NSCLC). 
      METHODS: Trials comparing Osimertinib against epidermal growth factor receptor 
      tyrosine kinase inhibitors (EGFR-TKIs)/chemotherapy in patients with NSCLC with 
      an epidermal growth factor receptor (EGFR) mutation were included, and the pooled 
      data for progression-free survival (PFS), overall survival (OS), overall response 
      rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed. 
      RESULTS: Analysis results based on 6 eligible trials showed that Osimertinib 
      significantly improved the overall PFS (hazard ratio [HR] = 0.38, 95% confidence 
      interval [CI] = 0.29-0.50), improved the OS (HR = 0.66, 95% CI = 0.48-0.89), 
      increased the ORR (odds ratio [OR] = 1.76, 95% CI = 1.14-2.72), increased the 
      overall DCR (OR = 1.18, 95% CI = 1.02-1.37), and reduced the grade 3 or greater 
      AEs (relative ratio [RR] = 0.50, 95% CI = 0.33-0.75) in all subgroups except in 
      the ORR in the Exon 19 deletion (Ex19del) and/or L858R subgroup. Compared to 
      patients with Ex19del and/or L858R mutation, patients with the T790M mutation had 
      the benefits of a greater PFS (41.7%), a greater ORR (80.0%), a greater DCR 
      (71.2%), and fewer grade 3 or greater AEs (70.7%) (each P < .05). Race, sex, age, 
      EGFR mutation, and smoking history may significantly predict additional benefits 
      from Osimertinib, but there were no significant differences between subgroups 
      stratified by these clinical characteristics. CONCLUSIONS: Osimertinib showed 
      greater treatment benefit for patients with NSCLC with EGFR mutation than 
      EGFR-TKIs/chemotherapy, especially for T790M mutation-positive patients.
FAU - Huang, Lei
AU  - Huang L
AD  - Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi 
      Medical University.
FAU - Huang, Hao
AU  - Huang H
AD  - Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi 
      Medical University.
FAU - Zhou, Xiao-Ping
AU  - Zhou XP
AD  - Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi 
      University of Chinese Medicine, Nanning, Guangxi, China.
FAU - Liu, Jin-Feng
AU  - Liu JF
AD  - Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi 
      Medical University.
FAU - Li, Chun-Rong
AU  - Li CR
AD  - Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi 
      Medical University.
FAU - Fang, Min
AU  - Fang M
AD  - Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi 
      Medical University.
FAU - Wu, Jun-Rong
AU  - Wu JR
AD  - Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi 
      Medical University.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Acrylamides)
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 3C06JJ0Z2O (osimertinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Acrylamides/*therapeutic use
MH  - Aniline Compounds/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*genetics
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*genetics
MH  - Mutation
MH  - Protein Kinase Inhibitors/*therapeutic use
PMC - PMC6824777
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/10/28 06:00
MHDA- 2019/11/07 06:00
PMCR- 2019/10/25
CRDT- 2019/10/26 06:00
PHST- 2019/10/26 06:00 [entrez]
PHST- 2019/10/28 06:00 [pubmed]
PHST- 2019/11/07 06:00 [medline]
PHST- 2019/10/25 00:00 [pmc-release]
AID - 00005792-201910250-00070 [pii]
AID - MD-D-19-03794 [pii]
AID - 10.1097/MD.0000000000017705 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Oct;98(43):e17705. doi: 10.1097/MD.0000000000017705.